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cense. httpAbstract Background and aim: Breast cancers (BCs) involve the left side (LS) more than the right
side (RS). Among the Egyptians, neither BC laterality nor its association with demographic factors,
tumor locations, treatments and outcomes were previously reported.
Patients and methods: Laterality was analyzed among 5459 BCs from the Gharbiah population-
based cancer registry covering >5% of the Egyptian population. Cox proportional model was used
to assess the independent effect of stage, ER, and laterality on overall survival (OS).
Results: In Egypt, BCs involve LS more than RS with LS-to-RS ratio (LRR) of 1.16. LS predom-
inance was evident among men and women and both younger (<45 years) and older patients.
HER2 over-expression and ductal cancers were signiﬁcantly more in RSBCs while lobular cancers
were signiﬁcantly more in LSBCs. There were no signiﬁcant differences in localization within the
breast between LSBCs and RSBCs (p= 0.51). LS predominance was noticed across all subgroups
except in patients with HER2 positive tumors (LRR= 0.63; p= 0.02). OS was signiﬁcantly better
in stage II and ER positive tumors than stage III and ER negative tumors. Despite OS of LSBCs
being generally lower than RSBCs, this was not statistically signiﬁcant. The signiﬁcant impact of
stage on OS was lost in LSBCs.
Conclusions: Among Egyptian patients, the left breast is at greater risk of cancer than the right one.
Despite right-sided tumors seemed more aggressive, Left-sided ones tend to confer worse survival
than right-sided tumors.
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Breast cancer (BC) is the most common female malignancy
accounting for 22.9% and 37.7% of all female cancers world-
wide and in Egypt, respectively [1–3]. BC in Egypt carries an
carries an
ational Cancer Institute, Cairo University.
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200 A.A. Zeeneldin et al.unfavorable prognosis with 29% mortality and 3.7:1 incidence
to mortality ratio [1].
BC was consistently reported to afﬂict the left breast more
than the right one [4–9]. Despite the causes for left-sided pre-
dominance (LSP) being unclear, it may reﬂect etiologic factors
not yet recognized or understood [10]. Increased trauma [4,6],
lactation dysfunction of the left breast [11] and breast-feeding
patterns [12] were suggested but they lack the supporting evi-
dence. As the left breast is slightly larger than the right due
to hemodynamic asymmetry, breast size was suggested as an
explanation for LSP [4,6,8]. However, the minimal increase
in size does not explain the magnitude of increased cancer risk
in the left compared to the right breast [6]. Furthermore, breast
size was proved not to be associated with BC risk [13]. Thus,
the breast parenchyma mass, or mammary gland cell mass,
may be a better predictor BC risk than the size [14]. It was also
suggested that LSP may reﬂect easier self-detection by the
right-handed patients that represent the majority of the popu-
lation [6,15]. However, this was not conﬁrmed [9,16].
LSP was mentioned to increase with age [6,8,9] and differs
with population race and ethnicity [10,12,13,16]. In a small
study, both total number and the number of involved axiliary
lymph nodes (ALNs) were smaller in left-sided BCs than the
right-sided ones [17].
Although the excess of left-sided tumors is not large and
does not appear to have major clinical implications [18], breast
or chest wall irradiation leads to higher radiation doses to the
heart in left-sided tumors compared to the right side [19]. This
might result in a greater cardiovascular mortality following
irradiation of the left breast when compared with the right
breast [20,21]. Thus, caution to cardiac exposure and new irra-
diation techniques that limit that exposure should be used in
left sided tumors. Also, the sequential or concomitant adminis-
tration of cardiotoxic drugs such as anthracyclines, cyclophos-
phamide and trastuzumab has to be properly planned [19].
It was reported that women living in Israel had various later-
ality patterns where those born in theMiddle East and Asia had
more right-sided tumors and those born in other regions had
left-sided tumors. The survival was not different at any stage
among right and left-sided tumors [22]. To the best of our
knowledge, neither laterality of BC among Egyptian patients
nor its association with various clinico-pathological characteris-
tics, treatments and disease outcomes have been reported.
Patients and methods
All cases of breast cancers diagnosed from 1999 to 2007 were
identiﬁed through the Gharbiah Population-based Cancer Reg-
istry (GPBCR), covering >5% of the Egyptian population.
The analyses were based on 5459 cases of invasive breast carci-
nomas. Subjects with non-invasive cancer (112 cases), bilateral
cancer (48 cases) or unknown laterality (432 cases), other non-
carcinoma histology (164 cases) or unspeciﬁed malignancy (409
cases) were excluded. The association between laterality and
treatments and their outcomes was assessed in a group of 283
patients whose information was available.
Statistical analyses
All analyseswere done usingMicrosoft Excel 2012 and SPSS
version 15. Chi squared test or Fisher’s Exact test were used tocompare right and left-sided BCs with other variables. Survival
was assessed using the Kaplan Meier Method and groups were
compared using the log-rank test. Cox proportional hazard
model was used to assess the independent effect of stage, ER,
PR and laterality on overall survival (OS). OS is deﬁned as the
time between diagnosis and death or last follow up. A probabil-
ity (p) < 0.05 is considered statistically signiﬁcant.Results
Out of 5459 cases of invasive breast cancers (BCs), 2928 cases
(53.64%) were left-sided and 2531 cases were right-sided
(46.36%). Overall, the left to right ratio (LRR) was 1.16.
LRR ranged between 1.04 and 1.27 (Table 1). There was no
signiﬁcant association between overall LRR and the year
(p= 0.56). Collectively and during individual years, left-sided
predominance (LSP) was also noted in males and females de-
spite the LRR was generally but non-signiﬁcantly higher in
males than females (p= 0.40). Reversed LRR (i.e. right-sided
predominance; RSP) was noted during the years 2003 and
2004. However, the numbers of male BCs were very small to
consolidate the ﬁnding.
The median age of patients with right-sided tumors was
49 years (IQR, 42–56) compared to 50 years (IQR, 43–57)
for those with left-sided tumors and this was not statistically
signiﬁcant (p= 0.33). The median age of patients with left
and right sided tumors increased with time (Fig. 1A). Left-
sided predominance was maintained across most various age
groups and in the younger (<45 years) compared to the older
women (Table 2). Nevertheless, women <25 years had RSP
and the numbers in this category were generally small. Later-
ality differences according to age groups were not statistically
signiﬁcant (p= 0.28).
Left-sided tumors involved the central and lower-inner
quadrants in 15.1% and 9.5%, respectively compared to
13.6% and 8.5% for right-sided tumors. Right-sided BCs
involved the upper-outer quadrant in 46.6% compared to
44.3% for left sided tumors (p= 0.51; Table 3). Apart from
decline of median tumor size in the year 2000, the median
tumor size for right and left BCs was stable at around 4 cm
(Fig. 1B). Apart from an initial drop in the year 2000, the med-
ian number of positive axillary lymph nodes (ALNs) slightly
ﬂuctuated around 5 (Fig. 1C). The total number of dissected
ALNs was not statistically different between right and left-
sided BCs and ﬂuctuated around the number 13 (Fig. 1D).
BC Laterality was signiﬁcantly associated with tumor his-
tology (p 6 0.001) where right-sided tumors had more ductal
(91.7% vs. 88.5%) and left-sided tumors had more lobular
cancers (8.7% vs. 5.1%). BC laterality was also associated with
HER2 expression (p= 0.02) where right-sided tumors had
more score 3 (33.9% vs. 21.3% and left-sided tumors had more
score 0–2 (78.7% vs. 66.1%; Table 4). LSP was noticed across
all subgroups except in tumors with HER2 score of 3 and T4
tumors where right-sided tumors predominated (Table 4).
TNM and SEER tumor stages and consequently different lines
of therapies were not statistically different between right- and
left-sided BCs. Treatments were encountered in comparable
percentage in left and right-sided tumors (Table 6) (p> 0.5
for all).
To associate the laterality with treatments and their out-
comes, we selected a subgroup of patients from the same
Table 1 Laterality of breast cancers (BCs) among 5495 Egyptian patients during the years 1999 till 2007.
Year Total BCs Left BCs Right BCs Overall LRR Male LRR Female LRR
N N % N %
1999 517 267 51.64 250 48.36 1.07 2.00 1.06
2000 490 253 51.63 237 48.37 1.07 1.50 1.06
2001 551 305 55.35 246 44.65 1.24 3.00 1.23
2002 576 320 55.56 256 44.44 1.25 3.00 1.24
2003 612 334 54.58 278 45.42 1.20 1.50 1.20
2004 650 332 51.08 318 48.92 1.04 0.50 1.05
2005 654 354 54.13 300 45.87 1.18 0.29 1.20
2006 702 368 52.42 334 47.58 1.10 2.50 1.08
2007 707 395 55.87 312 44.13 1.27 2.00 1.26
All years 5459 2928 53.64 2531 46.36 1.16 1.46 1.16
BC: breast cancer, LRR: left-to-right ratio.
Figure 1 Right and left-sided breast cancer between 1999 and 2007 according to median age at diagnosis (A), median tumor size (B),
Number of positive (C) and total (D) axillary lymph nodes.
Table 2 Left- and right-sided breast cancers (BCs) according
to age group.
Age group (years) Total BCs Left BCs Right BCs LRR
N N % N %
18–24 21 10 0.3 11 0.4 0.91
25–34 401 225 7.7 176 7.0 1.28
35–44 1350 696 23.8 654 25.9 1.06
45–54 1846 1009 34.5 837 33.1 1.21
55–64 1233 670 22.9 563 22.3 1.19
65–75 463 234 8.0 229 9.1 1.02
75+ 145 84 2.9 61 2.4 1.38
<45 1772 931 31.8 841 33.2 1.11
>45 3687 1997 68.2 1690 66.8 1.18
All groups 5459 2928 53.6 2531 46.4 1.16
BC: breast cancer, LRR: left-to-right ratio.
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vival. All had node-positive disease (N+) and were negative
for metastases (M0) i.e. stage II and III. This group counted
283 BCs representing 5.2% of the GPBCR cases. The character-
istics of this group are shown in Table 5 which were largely sim-
ilar to those of the GPBCR BC population. Overall, there was
LSP with a LRR of 1.05. The LSP in this patients’ subgroup
was less marked than the GPBCR cases as these are markedly
smaller. However, right-sided predominance was noted in
HER2 score of 3 + and in T4 tumors similar to GBPCR pa-
tients. Various treatment options detailed in Table 6 are not sig-
niﬁcantly different in left and right-sided tumors (Table 6).
After a median follow up of 25 months (range, 1–
67 months), 31 patients were dead; 17 patients with left sided
tumors and 14 patients with right sided tumors. The median
OS was not reached. The 2- and 5-year OS rates were 88.9%
and 81.42% respectively. OS was signiﬁcantly associated with
Table 3 Tumor localization in left- and right-sided breast cancers (BCs).
Breast cancer location Total BCs Left BCs Right BCs LRR
N N % N %
Central & nipple 607 337 15.1 270 13.6 1.25
UIQ 381 213 9.5 168 8.5 1.27
LIQ 187 102 4.6 85 4.3 1.20
UOQ 1913 991 44.3 922 46.6 1.07
LOQ 284 150 6.7 134 6.8 1.12
Axillary tail 88 51 2.3 37 1.9 1.38
Overlapping 758 394 17.6 364 18.4 1.08
All 4218 2238 100.0 1980 100.0 1.13
BC: breast cancer, LRR: left-to-right ratio, UIQ: upper-inner quadrant, LIQ: lower-inner quadrant, UOQ: upper-outer quadrant, LOQ: lower-
outer quadrant.
Table 4 Laterality of 5459 invasive breast cancers and their tumor characteristics.
Characteristic Total BC Left BCs Right BCs p LRR
N N % N %
Histology IDC 4914 2592 88.5 2322 91.7 <0.001 1.12
ILC 382 254 8.7 128 5.1 1.98
Mixed (IDC & ILC) 163 82 2.8 81 3.2 1.01
Grade (n= 4283) 1 51 26 1.1 25 1.2 0.98 1.04
2 3281 1741 76.6 1540 76.6 1.13
3 881 470 20.7 411 20.4 1.14
4 70 36 1.6 34 1.7 1.06
ER (n= 1983) Negative 573 320 30.4 253 27.2 0.12 1.26
Positive 1410 733 69.6 677 72.8 1.08
PR (n= 1576) Negative 566 314 37.6 252 34.1 0.15 1.25
Positive 1010 522 62.4 488 65.9 1.07
HER2 (n= 253) 0:2+ 185 111 78.7 74 66.1 0.02 1.19
3+ 68 30 21.3 38 33.9 0.63
SEER stage (n= 4751) Localized 517 24.7 1141 23.3 624 0.26 1.21
Regional 1411 61.2 2960 63.5 1549 1.10
Distant 293 14.1 650 13.2 357 1.22
T stage (n= 3191) 1 347 188 11.2 159 10.5 0.24 1.18
2 1912 1017 60.5 895 59.2 1.14
3 447 240 14.3 207 13.7 1.16
4 485 235 14.0 250 16.5 0.94
N stage (n= 4264) 0 1155 637 27.6 518 26.4 0.26 1.23
1 1265 676 29.3 589 30.1 1.15
2 1172 612 26.6 560 28.6 1.09
3 672 380 16.5 292 14.9 1.30
M stage (n= 3400) 0 2956 1568 86.9 1388 87.0 0.97 1.13
1 444 236 13.1 208 13.0 1.13
TNM stage group (n= 3984) I 165 86 4.0 79 4.3 0.63 1.09
II 1526 837 39.2 689 37.2 1.21
III 1848 974 45.6 874 47.2 1.11
IV 445 237 11.1 208 11.2 1.14
BC: breast cancer, LRR: left-to-right ratio, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor,
SEER, Surveillance Epidemiology and End Results, TNM: tumor, node, metastases.
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and 5-year OS rates for patients with left-sided tumors were
87.0% and 82.8% and for those with right-sided tumors were
90.8% and 80.5% (p= 0.607; Fig. 2).For left-sided tumors, the 2- and 5-year OS rates for pa-
tients with stage II disease were 91% and 88% and for those
with stage III were 85% and 79% (p= 0.366; Fig. 3A). For
right-sided tumors, The 2- and 5-year OS rates for patients
Table 6 Laterality of 283 invasive breast cancers and their treatment modalities.
Characteristic Total BC Left BCs Right BCs p LRR
N % N % N %
Surgery
BCS 40 14.0 19 13.1 21 15.2 0.61 0.90
MRM 243 86.0 126 86.9 117 84.8 1.08
Radiotherapy
No 33 11.7 15 10.3 18 13.0 0.48 0.83
Yes 250 88.3 130 89.7 120 87.0 1.08
Chemotherapy
No 12 4.2 5 3.4 7 5.1 0.57 0.71
Yes 271 95.8 140 96.6 131 94.9 1.07
Hormonal therapy (n = 264)
No 55 19.4 26 19.4 29 22.3 0.56 0.90
Yes 209 80.6 108 80.6 101 77.7 1.07
BC: breast cancer, LRR: left-to-right ratio, CBS: conservative breast surgery, MRM: modiﬁed radical mastectomy.
Table 5 Laterality of 283 invasive breast cancers and their tumor characteristics.
Characteristic Total BC Left BCs Right BCs p LRR
N N % N %
Total 283 145 51.2 138 48.8 – 1.05
Sex
Male 7 5 3.4 2 1.4 0.45 2.50
Female 267 140 96.6 136 98.6 1.03
Histology
Ductal 267 133 91.7 134 97.1 0.11 0.99
Lobular 14 10 6.9 4 2.9 2.50
Mixed ductal and lobular 2 2 1.4 0 0.0
Grade (n = 266)
1 1 1 0.7 0 0.0 0.27
2 251 124 92.5 127 96.2 0.98
3 13 9 6.7 4 3.0 2.25
4 1 0 0.0 1 0.8 –
ER (n = 261)
Negative 68 32 24.2 36 27.9 0.50 0.89
Positive 193 100 75.8 93 72.1 1.08
PR (n = 244)
Negative 60 28 23.0 32 26.2 0.55 0.88
Positive 184 94 77.0 90 73.8 1.04
HER2 (n = 133)
Non over-expressed (0–2+) 142 58 95.1 66 91.7 0.51 0.88
Over-expressed (3+) 9 3 4.9 6 8.3 0.50
T Stage
1 27 14 9.7 13 9.4 0.50 1.08
2 157 80 55.2 77 55.8 1.04
3 45 27 18.6 18 13.0 1.50
4 54 24 16.6 30 21.7 0.80
N stage
1 120 58 40.0 62 44.9 0.57 0.94
2 105 58 40.0 47 34.1 1.23
3 58 29 20.0 29 21.0 1.00
M0 stage 283 – – – – – –
TNM stage group
II 91 45 31.0 46 33.3 0.68 0.98
III 192 100 69.0 92 66.7 1.09
BC: breast cancer, LRR: left-to-right ratio, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor,
TNM: tumor, node, metastases.
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Figure 2 Overall survival in breast cancer regardless of stage (A) and according to stage (B).
Table 7 Overall survival rates in 283 breast cancer cases.
Item Group Numbers 2YSR (SE)% 5YSR (SE)% p
Whole group 283 99.2 (0.5) 97.2 (1.0) –
Sex Male 7 80.0 (17.9) 80.0 (17.9) 0.721
Female 276 99.2 (0.5) 96.2 (1.2)
Age 645 years 93 95.1 (2.4) 90.2 (3.6) 0.622
>45 years 190 99.4 (0.6) 93.5 (2.0)
Histology IDC 267 99.2 (0.6) 96.1 (1.3) 0.767
ILC 14 90.0 (9.5) 72.0 (17.8)
Grade Groups Low (G1 & 2) 252 99.2 (0.6) 95.4 (1.4) 0.788
High (G3 & 4) 14 90.9 (8.7) 80.8 (12.2)
ER Negative 68 77.6 (5.8) 71.4 (6.8) <0.001
Positive 193 99.4 (0.6) 95.5 (1.7)
PR Negative 60 80.3 (5.6) 77.4 (6.1) 0.049
Positive 184 99.4 (0.6) 94.7 (1.8)
Her2 Negative 124 96.3 (1.8) 90.1 (3.0) 0.547
Positive 9 80.0 (17.9) 80.0 (17.9)
TNM II 91 97.4 (1.8) 93.9 (3.0) 0.027
III 192 98.3 (1.0) 92.5 (2.1)
Radiotherapy No 33 85.6 (7.7) 85.6 (7.7) 0.688
Yes 250 99.1 (0.6) 95.4 (1.4)
Hormonal Therapy No 55 75.4 (6.5) 68.1 (7.7) <0.001
Yes 109 99.5 (0.5) 95.9 (1.5)
Chemotherapy No 12 100.0 100.0 0.353
Yes 271 99.2 (0.5) 95.8 (1.3)
Surgery BCS 40 97.3 (2.7) 97.3 (2.7) 0.090
MRM 243 99.6 (0.4) 95.7 (1.3)
Laterality Right 138 97.6 (1.4) 90.8 (2.8) 0.607
Left 145 98.5 (1.1) 90.3 (2.8)
2- or 5-YOSR: 1- or 5-year overall survival rate, SE: standard error, IDC: invasive duct carcinoma, ILC: invasive lobular carcinoma, ER:
estrogen receptor, PR: progesterone receptor, Her2: human epidermal growth factor receptor-2, BCS: breast conserving surgery, MRM:
modiﬁed radical mastectomy.
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were 86% and 79% (p= 0.026; Fig. 3B). For left-sided tu-
mors, the 2- and 5-year OS rates for patients with ER negative
tumors were 71% and 64% compared to 92% and 90% for ER
positive tumors, respectively (p= 0.002). For right-sidedtumors, the 2- and 5-year OS rates for patients with ER nega-
tive tumors were 82% and 76% compared to 96% and 76%
for ER positive tumors, respectively (p= 0.042) (Fig. 4).
The variables which were signiﬁcantly associated with OS
using the log-rank test were entered into a stepwise Cox
Figure 3 Overall survival in breast cancer according to stage both in the left (A) and right sides (B).
Figure 4 Overall survival of left-sided (A) and right-sided (B) breast tumors according to estrogen receptor status.
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monal treatment was an independent predictor of OS
(p= 0.002). The hazard of death in patients who did not re-
ceive hormonal treatment was 3.5 times the hazard in patients
who received hormonal therapy (CI: 1.6–7.4).
Discussion
This is the ﬁrst report from Egypt and the second from the
Middle East that reports on breast cancer laterality in a large
number of patients using population based registry data. The
earlier report [22] was more than 33 years ago and comments
on patients diagnosed in 1960 through 1975 in Israel whose
population is more diverse as it includes immigrants from
many world regions and thus belongs to many racial and eth-
nic groups. Early on, many of the now-available breast cancer
therapies were not known thus survival ﬁgures were generally
poor and the impact of modern prognostic factors like ER and
HER2 was not assessed. Our study includes a large number of
population-based breast cancer patients that belong almost to
one native race and assesses the impact of important prognos-
tic and therapeutic factors.
The previous ﬁndings of LSP of invasive BC [4–10,22] are
conﬁrmed in the current study. Due to the small numbers of
non-invasive carcinoma in GPBCR, we elected not include
them in the analysis and limit the analysis to invasive BCs that
we thought would be a homogenous group. However, manyauthors showed that LSP is noted for non-invasive as well as
invasive BCs [5,8,10].
The left to right ratio (LRR) in the current study was 1.12
compared to 1.05 in US [9,10], 1.07 in Sweden [8], 1.04 in Israel
[22]. It is lower than the LRR of 1.26 reported by Senie et al.
[6] and 1.18 reported by Tulinius et al. in Iceland [7]. Reasons
for the differences in BC laterality as well the LRR among var-
ious world regions are largely unknown and may reﬂect
unidentiﬁed risk factors [10]. However, there is an association
of the magnitude of LSP and sample size whereas studies with
larger samples [8–10,22] had lower LSP than those with a lar-
ger sample size [6,7].
In this retrospective study, we could not associate the later-
ality to the presumed reasons as data on reproductive history,
trauma, lactation, breast size/parenchymal mass or handed-
ness were not available through the GPBCR database. In the
current study, we could not study the effect of race on BC lat-
erality as race data were lacking in GPBCR. However, the
population of Gharbiah District is rather homogenous and
consists of natives [23]. Our ﬁnding of LSP contradicts with
that from Israel that showed that patients born in the Middle
East or in Asian countries had a predominance of right sided
tumors and those born elsewhere had LSP [22]. However,
the latter report involved a small number of patients in this
category. Laterality reports that involved thousands of
patients in different race and ethnicity populations showed a
consistent LSP [8–10,22].
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study period with a LRR of 1.46. This is similar to [4–8,10].
In agreement with Perkins et al. [10], we have shown that
age was not signiﬁcantly associated with laterality. Our ﬁnding
of the predominance of right-side tumors in patients below
25 years needs further veriﬁcation as the numbers in this cate-
gory are small. In agreement with Perkins et al. [10], but con-
tradicting with others [4,6–8], we showed that LSP was not
different between patients aged <45 years or >45 years. How-
ever, the studies that showed this association were relatively
smaller trials [4,6–8].
We have shown that the LSP mainly involved the central
and upper inner quadrants. This is different from the LSP in
the inner half reported by Perkins et al. [10]. The reasons for
this are unknown as there are no known physiological, patho-
logical, or immunological differences between the lower, but
not upper, left and right breasts that would explain for these
ﬁnding. However, it should be noted that up to 25% of cases
in the current had undetermined breast localization. If these
were known, ﬁgures may have changed.
For the ﬁrst time, we studied the relation between laterality
and receptor status. Compared to left-sided tumors, right-sided
ones were more likely to have HER2 score of 3+ (p= 0.02)
and to have T4 disease (p= 0.24). These novel ﬁndings had no
explanation and may need further conﬁrmation. If proven, this
maymean that left tumors may be less aggressive than right ones.
In the current study, stage III and ER negativity conferred
signiﬁcantly lower survival than stage II and ER positivity. We
showed that OS was generally, yet non-signiﬁcantly, poorer in
left than right-sided tumors. However, left sided localization
abolished the apparent signiﬁcant difference between stages
III and II observed in the total group as well as in the right-
side localization. Thus, the ﬁnding by Melnik et al. [22] that
OS was not different between right- and left-sided breast tu-
mors at any stage partially contradicts our ﬁnding. The men-
tioned trial included patients during the time between 1960
and 1975 when modern therapies available today were not
widely used. This inferred a poor prognosis of their patients
compared to the current study. The loss of survival beneﬁt in
stage II compared to stage III tumors of the left side may be
explained by the fact that all of the patients in the current
study were node positive and most of them received radiother-
apy with possible damage to the heart. Cardiac deaths in left
sided tumors are well-recognized [19]. Thus, poor survival of
left-sided tumors may not be related to the site per se but
rather to the toxicity of radiation to this site that entails more
exposure of the heart. However, cause-speciﬁc morality was
not ascertained in most of our patients.
In conclusion, predominance of left-sided breast tumors
over the right is conﬁrmed among Egyptian patients. Right-
sided tumors had more tendencies to afﬂict very young pa-
tients, to present as T4 and to be HER2 positive. Left-sided tu-
mors tend to confer worse survival compared to right-sided
tumors, possibly related to radiation toxicity to the heart in
left-sided cancers. Further research to explain the reasons for
these differences is warranted.Conﬂict of interest
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